German biotechnology company BioNTech is set to close three of its sites in Germany after efforts to find potential buyers for the facilities did not result in agreements. The planned closures are part of the company's broader strategy to consolidate its global manufacturing network and redirect resources toward its growing oncology pipeline.
The sites affected are located in Idar-Oberstein, Marburg and Tübingen. The restructuring could affect up to approximately 1,860 positions, according to BioNTech's previously announced manufacturing-footprint consolidation plan.
Buyer Search Did Not Result in Agreements
BioNTech had been exploring divestment options for the affected manufacturing locations, including potential partial or complete sales. In an update earlier this year, the company said it was evaluating possible buyers as part of its planned manufacturing-footprint consolidation.
However, the latest development indicates that no suitable buyer agreements were reached for the three German sites, leading BioNTech to proceed with the planned closures. Reuters reported that the company had undertaken extensive efforts to find buyers before deciding to shut the facilities.
Why Is BioNTech Consolidating Its Manufacturing Network?
BioNTech said its manufacturing network is being adjusted in response to changing supply requirements, expected excess capacity, manufacturing capabilities available through partners, mergers and acquisitions, and the completion of certain contracts.
The company previously stated that the consolidation is intended to improve capital efficiency and support its transition toward becoming a multi-product biopharmaceutical company, with a significant focus on oncology.
BioNTech has also said that the affected facilities are expected to become underutilized or idle over the coming period and that the consolidation is not expected to affect commercial or clinical supply commitments.
Closures Are Part of a Larger Restructuring
The German closures are part of a wider manufacturing restructuring. BioNTech has also been reviewing its manufacturing footprint outside Germany, including operations in Singapore and sites associated with CureVac.
The company said the measures could eventually generate approximately €500 million in recurring annual savings once fully implemented in 2029. BioNTech intends to use the improved capital efficiency to advance its pipeline, particularly its oncology programs.
The company has emphasized that it continues to maintain an established manufacturing network intended to support its commercial and clinical supply requirements.
What It Means for Employees
The planned closures could affect up to approximately 1,860 positions across the broader manufacturing-footprint consolidation program. BioNTech has said it is working with employee representatives on solutions for affected workers, including redundancy-related measures.
The development highlights the continuing changes taking place in the pharmaceutical manufacturing sector following the exceptional production requirements created during the COVID-19 pandemic.
